Preclinical | Phase 1 | Phase 2 | Phase 3/4 | Marketed | |
---|---|---|---|---|---|
Cardiovascular disease |
SP-8416 Heart failure |
SP-8356 Stroke, Atherosclerosis |
Otaplimastat Acute ischemic stroke |
CandeAmlo¢ç Hypertension |
|
Otaplimastat ALS Additional Indication |
CandeAmlo plus¢â Hypertension |
EzeRosu¢ç Hyperlipidemia |
|||
SP-8257 Stroke, Atherosclerosis |
|||||
Bone related disease |
Hyalflex¢ç Osteoarthritis |
||||
Hyaltop¢ç Osteoarthritis |
|||||
Medical Device |
SP5V005 Anti-adhesion, Additional Function |
Medicurtain¢ç Anti-adhesion |
|||
Infectious disease |
Pyramax¢ç tablets COVID-19 Drug repurposing |
Pyramax¢ç tablets Malaria WHO-MMV |
|||
Pyramax¢ç granules Malaria WHO-MMV |